It binds with roughly equivalent high affinity (0.7–9.1 nM) to the benzodiazepine binding site of human GABAA receptors containing either an α1, α2, α3 or α5 subunit. It is a partial agonist at α1-, α2- and α5-containing GABAA receptors and a full agonist at receptors containing an α3 subunit. In rats 5′-hydroxypagoclone was identified as a major metabolite. This metabolite has a considerably greater efficacy at the α1 subtype than the parent compound and was shown to have significant anxiolytic-like activity and to produce sedation.[2][3] In contrast to zopiclone, pagoclone produces anxiolytic effects with little sedative or amnestic actions at low doses.[4]

12 marca 2020mukbak pisze:

Pagoklon nie był kiedyś stosowany w Polskiej Farmakoterapii? Czy mi się wydaje? Wie ktoś może, czemu go wycofali? Nie podpada pod prawo anologowe, bo to niebenzodiazepina :p